Collplant Biotechnologies Ltd

CEO Tal Yehiel Sticks to CollPlant Biotech’s 80% Stock Decline with 90,000+ Shares and Options Locked‑In for 2028

CollPlant’s CEO holds significant long‑term equity, underscoring management’s confidence in 3D bioprinting and orthobiologics despite an 80% price drop.

Collplant Biotechnologies Ltd
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

19/03/2026, 22:27

3 minutes to read

CEO CollPlant Stays the Course: Insider Holdings Show Long‑Term Faith Amid 80% Decline

CEO Tal Yehiel’s steady shareholdings show long‑term confidence in CollPlant’s 3D bioprinting future, hinting at potential stability despite a steep stock decline.

Collplant Biotechnologies Ltd
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

19/03/2026, 21:57

2 minutes to read